Researchers validate first-ever AI biomarker for ADT benefit in prostate cancer

Data from a new study published in NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermediate-risk prostate cancer.

Related Keywords

Case Western Reserve University ,Ohio ,United States ,Canada ,Americans ,American ,Lee Seidman ,Daniel Spratt ,Theodoros Teknos ,Danielle Ellis ,Vincentk Smith ,Gary Schwartz ,Danieli Simon ,Cancer Center ,Department Of Radiation Oncology ,Case Comprehensive Cancer Center ,University Hospitals Uh Seidman Cancer Center ,Academic External Affairs ,University Hospitals ,Case Comprehensive Center ,Uh Seidman Cancer Center ,Seidman Cancer ,Northeast Ohio ,Radiation Oncology ,Case Western Reserve ,Case Comprehensive Cancer ,African American ,University Hospitals President ,External Affairs ,Chief Scientific Officer ,Patti Novak Distinguished Chair ,Healthcare Leadership ,Scientific Director ,Lee Seidman Chair ,Cancer Innovation ,Seidman Cancer Center ,African Americans ,Cancer ,Androgen ,Androgen Deprivation Therapy ,Artificial Intelligence ,Biomarker ,Children ,Hospital ,Medicine ,Ncology ,Prostate ,Prostate Cancer ,Radiotherapy ,Research ,Technology ,